Continuing EGFR-TKI beyond radiological progression in patients with advanced or recurrent, EGFR mutation-positive non-small-cell lung cancer: an observational study

BACKGROUND: Some patients with advanced or recurrent, epidermal growth factor receptor (EGFR) mutation-positive (EGFR M+) non-small-cell lung cancer (NSCLC) continue to receive EGFR tyrosine kinase inhibitors (TKIs) beyond radiological progression. METHODS: We analysed a cohort of 577 patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Goto, Yasushi, Tanai, Chiharu, Yoh, Kiyotaka, Hosomi, Yukio, Sakai, Hiroshi, Kato, Terufumi, Kaburagi, Takayuki, Nishio, Makoto, Kim, Young Hak, Inoue, Akira, Hasegawa, Yoshinori, Isobe, Hiroshi, Tomizawa, Yoshio, Mori, Yoshiaki, Minato, Koichi, Yamada, Kazuhiko, Ohashi, Yasuo, Kunitoh, Hideo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604715/
https://www.ncbi.nlm.nih.gov/pubmed/29018574
http://dx.doi.org/10.1136/esmoopen-2017-000214

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604715/
https://www.ncbi.nlm.nih.gov/pubmed/29018574
http://dx.doi.org/10.1136/esmoopen-2017-000214

Ejemplares similares